SAB4200795
Anti-Exendin-4 antibody produced in rabbit
affinity isolated antibody
Synonym(s):
Anti-Exenatide
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
concentration
~1 mg/mL
technique(s)
indirect ELISA: 0.125-0.25 μg/mL using 1 μg/mL Exendin-4 protein for coating
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
General description
Exendin-4 is an incretin mimetic 39-amino-acid peptide found in venom from the Gila monster (Helicoderma suspectum). Exendin-4 belongs to the glucagon-secretin family of peptide hormones and neuropeptides. It acts as a potent agonist of the GLP-1 receptor and is an insulinotropic agent (promotes insulin secretion) with a long half-life.
Exendin-4 mimics the activity of mammalian incretin hormone glucagon-like peptide 1 (GLP-1) and thus play a role in the control of glucose. This includes the secretion of insulin in a glucose-dependent manner, negative regulation of high glucagon secretion, and increased duration of stomach emptying. In type 2 diabetes patients, this peptide can be administered subcutaneously for glycemic control, when metformin is unable to produce adequate results. Exendin-4 promotes the neogeneration and proliferation of β-cells, and thus aids in the regeneration of pancreas. It acts as a ligand to exendin receptor and leads to an elevation of acinar cell cAMP levels.
Anti-Exendin-4 antibody specifically recognizes synthetic Exendin-4 and does not cross react with GLP-1.
Exendin-4 mimics the activity of mammalian incretin hormone glucagon-like peptide 1 (GLP-1) and thus play a role in the control of glucose. This includes the secretion of insulin in a glucose-dependent manner, negative regulation of high glucagon secretion, and increased duration of stomach emptying. In type 2 diabetes patients, this peptide can be administered subcutaneously for glycemic control, when metformin is unable to produce adequate results. Exendin-4 promotes the neogeneration and proliferation of β-cells, and thus aids in the regeneration of pancreas. It acts as a ligand to exendin receptor and leads to an elevation of acinar cell cAMP levels.
Anti-Exendin-4 antibody specifically recognizes synthetic Exendin-4 and does not cross react with GLP-1.
Immunogen
synthetic peptide corresponding to the C-terminal sequence of Heloderma suspectum (Gila monster) Exendin-4 , conjugated to KLH
Application
The antibody may be used in various immunochemical techniques including ELISA
Physical form
Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Other Notes
This product is for R&D use only, not for drug, household, or other uses.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yahiya Y Syed et al.
Drugs, 75(10), 1141-1152 (2015-06-14)
Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of
Ralph A DeFronzo et al.
Diabetes care, 28(5), 1092-1100 (2005-04-28)
This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses. A triple-blind, placebo-controlled, 30-week study at 82 U.S. sites
J Eng et al.
The Journal of biological chemistry, 267(11), 7402-7405 (1992-04-15)
The recent identification in Heloderma horridum venom of exendin-3, a new member of the glucagon superfamily that acts as a pancreatic secretagogue, prompted a search for a similar peptide in Heloderma suspectum venom. An amino acid sequencing assay for peptides
Masayuki Arakawa et al.
Diabetes, 59(4), 1030-1037 (2010-01-14)
Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the
G Xu et al.
Diabetes, 48(12), 2270-2276 (1999-12-02)
Diabetes is a disease of increasing prevalence in the general population and of unknown cause. Diabetes is manifested as hyperglycemia due to a relative deficiency of the production of insulin by the pancreatic beta-cells. One determinant in the development of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service